January 21, 2008
Prospector
Profile
118-01
 
Competitive Technologies, Inc. NAICS 533110
777 Commerce Drive, Suite 100 Fairfield, CT 06825 Description Patent Owner & Lessor
(203) 368-6044 Employees 15
http://www.competitivetech.net/ Revenue (mil) 4.1700
  Income (mil) -8.8900
  Assets (mil) 9.7100
  Liability (mil) 2.1100
  (for the year ended 2007-07-31)
 
Category: Loss/Deficit
 
Event: Competitive Technologies, Inc., had a net loss of $2,559,644 on revenues of $ 210,609 for the first quarter ended October 31, 2007, compared with a net loss of $1,122,162 on revenues of $895,176 for the same period last year. The Company's balance sheet at October 31, 2007, showed an accumulated deficit of $30,874,988 and stockholders' equity of only $4,657,860.
 
Intellectual Property: The Company has a concentration of retained royalties derived from its Homocysteine assay technology. The homocysteine assay is a diagnostic blood test used to determine homocysteine levels and a corresponding deficiency of folate or vitamin B12. The Company is actively marketing its other technologies, and seeking new technologies to mitigate this concentration of revenues and provide a steadier future revenue stream. These technologies include Ethyol™, Gallium arsenide and Sexual dysfunction. The Company also has other technologies in its life sciences portfolio, applied science/electronics portfolio and physical sciences portfolio. [SEC Filing 10KSB 10-29-2007]
 
Description: Competitive Technologies, Inc., provides technology transfer, selling and licensing services to intellectual property owners worldwide.
 
Officers: John B. Nano (Pres., CEO & Interim Chief Financial Officer); Aris D. Despo (EVP-Business Development)
 
Auditor: Mahoney Cohen & Company CPA PC
 
Securities: Common Stock-Symbol CTT; AMEX; 8,169,872 common shares outstanding as of December 13, 2007.
 
 
 
return to main page